Initial Announcement of 7th International Conference on Drug Discovery and Toxicology

The “7th International Conference on Drug discovery and toxicology” going to held in Helsinki, Finland on July  13-14  with the theme “Strategies Trends and Technologies for Drug Discovery and toxicology”.

The session is going to be tremendously useful and interactive stage with workshops, seminars, special sessions with experts like Pharmacologist, R&D Researchers, R&D Researchers, Pharmacists, Clinical Pharmacists, Scientist, Toxicologist, Doctors, Medical writers, Academic Professors, Deans and Students from, Pharmacology, Medicinal chemistry, and pharmaceutics, Directors, and members of pharmaceuticals Companies.

Drug discovery is a process of categorizing a   novel medicine or drug Medicinal chemistry, and pharmaceutics, Directors, and members of pharmaceuticals Companies.by an individual person  using diverse principles of science such as pharmacology, chemistry, and biology. In the past, the active pharmaceutical ingredient (API) was identified from accidental discoveries such as Penicillin. But currently, drug discovery is of identifying a lead component and its optimization. Drug development involves a sequence of steps for fetching out the newly identified drug into the market after its identification by a process of drug discovery.

Drug discovery consists of different stages, such a lead identification, product characterization, Formulation, Delivery, Packing, Preclinical trails and Clinical trails. IN Preclinical trails the scientist conducts an experimental test for  their identified new chemical entities (NCE) on animals such as rats, mice, dogs, and  monkeys  in a laboratory  This phase consists of all the factors which have to be there before using it on humans. In clinical trials or research, the test is done on humans who are both healthy and diseased. Its aim is to collect more data on the disease and its management. Medical devices are used for better patient compliance.

Biofilm disruption of Salmonella Typhimurium by a human antibody that binds a pan-amyloid epitope to curli.  These Bacterial biofilms which specifically those belonging to implanted medical devices, are hard to eradicate. Curli amyloid fibers are key components of the Enterobacteriaceae family formed by biofilms. The human monoclonal antibody with pan-amyloid-binding activity (mAb 3H3) can interrupt biofilms made by Salmonella Enterica Serovar Typhimurium in vitro and in vivo. The antibody interrupts the biofilm structure, and improve biofilm eradication by antibiotics and immune cells. Thus, monoclonal antibodies that bind to the pan-amyloid epitope will have the potentials to stop or eliminate the bacterial biofilms.

For more details:  https://drugchemistry.pharmaceuticalconferences.com/

Contact:

Amelia David

Program Manager

Drug Discovery Congress 2020

drugchemistry@memeetings.com